Skip to main content

Table 3 Correlation between nuclear REDD1 expression and clinicopathologic factor

From: Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma

Characteristic REDD1 expression Total No. χ2 P-value
Negative Positive
No. (%) No. (%)
Age 0.508*
 20- 5(83.3) 1(16.7) 6   
 30- 6(60.0) 4(40.0) 10   
 40- 37(80.4) 9(19.6) 46   
 50- 49(80.3) 12(19.7) 61   
 60- 66(85.7) 11(14.3) 77   
 70- 19(76.0) 6(24.0) 25   
 80- 4(100.0) 0(0.0) 4   
Stage 3.4 0.334
 Stage I 25(75.8) 8(24.2) 33   
 Stage II 20(71.4) 8(28.6) 28   
 Stage III 115(84.6) 21(15.4) 136   
 Stage IV 26(81.3) 6(18.8) 32   
Histologic type 0.043*
 Serous carcinoma 105(84.0) 20(16.0) 125   
 Mucinous carcinoma 6(100.0) 0(0.0) 6   
 Endometrioid carcinoma 24(77.4) 7(22.6) 31   
 Clear cell carcinoma 7(50.0) 7(50.0) 14   
 Mixed-type carcinoma 44(83.0) 9(17.0) 53   
Ascites 3.633 0.161
 Yes 108(78.8) 29(21.2) 137   
 No 49(80.3) 12(19.7) 61   
 Unknown 29(93.5) 2(6.5) 31   
Chemotherapy response 0.801*
 Completely Responders 130(81.8) 29(18.2) 159   
 Partial responders 34(82.9) 7(17.1) 41   
 Non responders 14(73.7) 5(26.3) 19   
 NC/URa 8(80.0) 2(20.0) 10   
CA125 0.750*
  < 500 50 (78.1) 14 (21.9) 64   
  ≥ 500 54 (83.1) 11 (16.9) 65   
 Unknown 82 (82.0) 18 (18.0) 100   
  1. *Fisher’s exact test
  2. aNC/UR: No chemotherapy or Unknown response